Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-01-18
1998-02-10
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544234, 544237, C07D23730
Patent
active
057169560
ABSTRACT:
Substituted dihydrophthalazine compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.
REFERENCES:
patent: 2832769 (1958-08-01), Armstrong
patent: 3012033 (1961-12-01), Engelbrecht et al.
patent: 3022305 (1962-02-01), Carboni
patent: 3249611 (1966-05-01), Hirach et al.
patent: 3274185 (1966-09-01), Sigal et al.
patent: 3753988 (1973-08-01), Rodway et al.
patent: 3880881 (1975-04-01), Singh
patent: 4963676 (1990-10-01), Strekowski et al.
patent: 5089494 (1992-02-01), Iwase et al.
patent: 5110347 (1992-05-01), Selby
patent: 5643911 (1997-07-01), Yamada et al.
Wilding T. Molecular Pharmacol. vol. 47 pp. 582-587 1995.
Donevan, S Jour. Pharmac. and Exptc Therap vol. 271 pp. 25-29 1994.
Zorumski, C. Neuron vol. 10 pp. 61-67 1993.
Chen et al., "Evaluation of Five Methods for Testing Anticonvulsant Activities," Proc. Sco. Exp. Biol. Med., 87:334 (1954).
Donevan and Rogawski, "GYKI 52466,a.alpha.2,3-Benzodiazepine, Is a Highly Selective, Noncompetitive Antagonist of AMPA/kainate Receptor Responses," Neuron, 10:51--59 (1993).
Hussy and et al., "Function Properties Of A Cloned 5-hydroxytryptamine Ionotropic Receptor Subunit :Comparison With Native Mouse Receptors," J. Physiol. (Lond.), 481.2:311-323 (1994).
Lipton and Rosenberg, "Excitatory Amino Acids As A Final Common Pathway For Neurologic Disorders," New England Journal of Medicine, 330:613-622 (1994).
McBurney, "Therapeutic Potential of NMDA Antagonists in Neurodegenerative Diseases," Neurobiology of Aging, 15:271-273 (1994).
Meldrum and Smith, "Cerebroprotective Effect of a Non-N-Methyl-D-Aspartate Antagonist, GYKI 52466, After Focal Ischemia in the Rat," Stroke 23:861 (1992).
Meldrum, "Excitatory Amino Acids in Epilepsy and Potential Novel Therapies," Epilepsy Research, 12:189-196 (1992).
Peillet et al., "The non-NMDA antagonists, NBOX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischamia in he rat," Brain Res., 571:115 (1992).
Yamaguchi et al., "Anticonvulsant Activity of AMPA/kainate antagonists:Comparison of GYKI 52466 and NBOX in Maximal Electroshock and Chemoconvulsant Seizure Models," Epilepsy Research, 15:179-184 (1993).
Tarnawa et al., "Electrophysiological Studies With a 2,3-benzodiazepine Muscle Relaxant:GYKI 52466,"Eur. J. Pharmacol., 167:193-199 (1989).
Pelletier et al. Jour. Med. Chem vol. 39 No. 2 pp. 343-346 (Jan. 19, 1996).
Bearsden Bearsden Bio, Inc.
Daus Donald G.
LandOfFree
Dihydrophthalazine antagonists of excitatory amino acid receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydrophthalazine antagonists of excitatory amino acid receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydrophthalazine antagonists of excitatory amino acid receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2077553